Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence
After High-Profile Setbacks In The Clinic
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."
